Early Toxicology Signal Generation in the Mouse

Toxicologic Pathology

Volumn 38, Issue 3, 2010, Pages 452-471

  Kramer, Jeffrey A ^a   O’neill, Emily ^a   Phillips, Megan E ^a   Bruce, Debra ^a   Smith, Traci ^a   Albright, Melinda M ^a   Bellum, Sairam ^a   Gopinathan, Suma ^a   Heydorn, William E ^a   Liu, Xuemei ^a   Nouraldeen, Amr ^a   Payne, Bobby Joe ^a   Read, Robert ^a   Vogel, Peter ^a   yu, Xiang Qing ^a   Wilson, Alan G E ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

discovery; mouse in vivo; preclinical; safety assessment; toxicology

Indexed keywords

ANTINEOPLASTIC AGENT; FENCLONINE; LP 499399; LP 527795; METHOTREXATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DIGESTIVE SYSTEM; DRUG SAFETY; DRUG STRUCTURE; HEMOLYSIS; IN VIVO STUDY; KIDNEY INJURY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PANCREAS INJURY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; TOXICITY TESTS;

RATTUS; RODENTIA;

EID: 77952483017     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623310364025     Document Type: Article

References (101)

1. Abdo K. M. Haseman J. K. Nyska A. (1998). Isobutyraldehyde administered by inhalation (whole body exposure) for up to thirteen weeks or two years was a respiratory tract toxicant but was not carcinogenic in F344/N rats and B6C3F1 mice. Toxicol Sci 42, 136–51.
2. Alfieri A. B. Cubeddu L. X. (1995). Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients. Br J Cancer 71, 629–32.
3. Almeida R. M. Correa B. Xavier J. G. Mallozzi M. A. Gambale W. Paula C. R. (1996). Acute effect of aflatoxin B1 on different inbred mouse strains II. Mycopathologia 133, 23–9.
4. Al-Shabanah O. A. Badary O. A. Al-Gharably N. M. Al-Sawaf H. A. (1998). Effects of L-histidinol on the antitumour activity and acute cardiotoxicity of doxorubicin in mice. Pharmacol Res 38, 225–30.
5. Ashby J. Lefevre P. A. Tinwell H. Brunborg G. Schmezer P. Pool-Zobel B. Shanu-Wilson R. Holme J. A. Soderlund E. J. Gulati D. (1991). The non-genotoxicity to rodents of the potent rodent bladder carcinogens o-anisidine and p-cresidine. Mutat Res 250, 115–33.
6. Beland F. A. (1999). NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice. Toxic Rep Ser 11, 1–66, A61–7.
7. Bieger W. Kern H. F. (1975). Studies on intracellular transport in the rat exocrine pancreas. I. Inhibition by aromatic amino acids in vitro. Virchows Arch A Pathol Anat Histol 367, 289–305.
8. Bieger W. Wacker P. Forssmann W. G. (1971). The mechanism of pancreatic secretion inhibited by p-chlorophenylalanine (PcPA). Verh Anat Ges 66, 87–96.
9. Biswas S. J. Pathak S. Khuda-Bukhsh A. R. (2004). Assessment of the genotoxic and cytotoxic potential of an anti-epileptic drug, phenobarbital, in mice: a time course study. Mutation Research 563, 1–11.
10. Blot C. Lebrec H. Roger R. Bohuon R. Pallardy M. (1994). Immune parameters are affected differently after cyclosporine A exposure in Fischer 344 rats and B6C3F1 mice: implications for immunotoxicology. Toxicology 94, 231–45.
11. Boston Consulting Group (2003). A revolution in R&D: How genomics and genetics will affect drug development costs and times. In PAREXEL’s Pharmaceutical R&D Statistical Sourcebook 2002/2003.
12. Boverhof D. R. Burgoon L. D. Tashiro C. Sharratt B. Chittim B. Harkema J. R. Mendrick D. L. Zacharewski T. R. (2006). Comparative toxicogenomic analysis of the hepatotoxic effects of TCDD in Sprague Dawley rats and C57BL/6 mice. Toxicol Sci 94, 398–416.
13. Bucci T. J. Howard P. C. Tolleson W. H. Laborde J. B. Hansen D. K. (1998). Renal effects of fumonisin mycotoxins in animals. Toxicol Pathol 26, 160–4.
14. Burka L. (2004). NTP technical report on the toxicity studies of Butanal Oxime (CAS No. 110-69-0) administered in drinking water and by gavage to F344/N rats and B6C3F1 mice. Toxic Rep Ser 69, 1–F10.
15. Car B. D. (2006). Enabling technologies in reducing drug attrition due to safety failures. American Drug Discovery 1, 53–6.
16. Chan P. (1993). NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) administered by gavage to F344 rats and B6C3F1 mice. Toxic Rep Ser 27, 1–D9.
17. Chan P. C. (1996). NTP technical report on toxicity studies of urethane in drinking water and urethane in 5% ethanol administered to F344/N rats and B6C3F1 mice. Toxic Rep Ser 52, 1-91, A91-99, B91–9, passim.
18. Chan P. C. (2004). NTP technical report on the toxicity studies of 2- and 4-Methylimidazole (CAS No. 693-98-1 and 822-36-6) administered in feed to F344/N rats and B6C3F1 mice. Toxic Rep Ser 67, 1–G12.
19. Chan P. C. Hills G. D. Kissling G. E. Nyska A. (2007). Toxicity and carcinogenicity studies of 4-methylimidazole in F344/N rats and B6C3F1 mice. Arch Toxicol 82, 45–53.
20. Chen P. Arias A. E. Morisset J. Calvo E. Dagorn J. C. Iovanna J. Bendayan M. (1996). Presence of pancreatitis-associated protein in pancreatic acinar cells of rats treated with chlorophenylalanine methyl ester. Pancreas 13, 147–53.
21. Chhabra R. S. (2000). NTP technical report on the toxicity studies of benzophenone (CAS No. 119-61-9). Administered in feed to F344/N rats and B6C3F mice. Toxic Rep Ser 61, 1–53, A51–13.
22. Cigremis Y. Parlakpinar H. Polat A. Colak C. Ozturk F. Sahna E. Ermis N. Acet A. (2006). Beneficial role of aminoguanidine on acute cardiomyopathy related to doxorubicin-treatment. Mol Cell Biochem 285, 149–54.
23. Dieter M. (1993). NTP technical report on the toxicity studies of ethylene glycol ethers: 2-methoxyethanol, 2-ethoxyethanol, 2-butoxyethanol (CAS Nos. 109-86-4, 110-80-5, 111-76-2) administered in drinking water to F344/N rats and B6C3F1 mice. Toxic Rep Ser 26, 1–G15.
24. Dunnick J. (1993). NTP technical report on the toxicity studies of ortho-, meta-, and para- nitrotoluenes (CAS Nos. 88-72-2, 99-08-1, 99-99-0) administered in dosed feed to F344/N rats And B6C3F1 mice. Toxic Rep Ser 23, 1–E4.
25. Engelman K. Lovenberg W. Sjoerdsma A. (1967). Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome. N Engl J Med 277, 1103–8.
26. Fielden M. R. Kolaja K. L. (2008). The role of early in vivo toxicity testing in drug discovery toxicology. Expert Opin Drug Saf 7, 107–10.
27. Foley J. F. Collins J. B. Umbach D. M. Grissom S. Boorman G. A. Heinloth A. N. (2006). Optimal sampling of rat liver tissue for toxicogenomic studies. Toxicol Pathol 34, 795–801.
28. Forssmann W. G. Bieger W. (1973). Biosynthesis of false proteins: incorporation of p-chlorophenylalanine into enzymes of the exocrine pancreas. Res Exp Med (Berl) 160, 1–20.
29. Furuse M. Satoh S. Yang S. I. Watanabe T. Okumura J. (1993). p-Chlorophenylalanine damages pancreatic acinar cell of the chicken. Comp Biochem Physiol C 106, 667–70.
30. Genestier L. Paillot R. Quemeneur L. Izeradjene K. Revillard J. P. (2000). Mechanisms of action of methotrexate. Immunopharmacology 47, 247–57.
31. Ghanayem B. I. (2000). NTP technical report on the toxicity studies of methacrylonitrile (CAS No. 126-98-7). Administered by gavage to F344/N rats and B6C3F1 mice. Toxic Rep Ser 47, 1–56, A51–E56.
32. Greaves P. Williams A. Eve M. (2004). First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov 3, 226–36.
33. Hamadeh H. K. Bushel P. R. Jayadev S. Martin K. DiSorbo O. Sieber S. Bennett L. Tennant R. Stoll R. Barrett J. C. Blanchard K. Paules R. S. Afshari C. A. (2002). Gene expression analysis reveals chemical-specific profiles. Toxicol Sci 67, 219–31.
34. Harvilchuck J. A. Carlson G. P. (2006). Comparison of styrene and its metabolites styrene oxide and 4-vinylphenol on cytotoxicity and glutathione depletion in Clara cells of mice and rats. Toxicology 227, 165–72.
35. Hebert C. (1993). NTP technical report on the toxicity studies of 1,6-hexanediamine dihydrochloride (CAS No. 6055-52-3) administered by drinking water and inhalation to F344/N rats and B6C3F1 mice. Toxic Rep Ser 24, 1–D8.
36. Huang T. S. Yang R. S. Tsai T. W. Liu S. H. (2004). Growth hormone cannot enhance the recovery of dexamethasone-induced osteopenia after withdrawal in young female wistar rats. Tohoku J Exp Med 204, 257–66.
37. ICH (1997). ICH harmonized tripartite guideline: non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals M3. Federal Register 62, 62922.
38. Jarvis M. F. Wagner G. C. (1985). Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine. Life Sci 36, 249–54.
39. Kari F. (1993). NTP technical report on the toxicity studies of glutaraldehyde (CAS No. 111-30-8) administered by inhalation to F344/N rats and B6C3F1 mice. Toxic Rep Ser 25, 1–E10.
40. Kim D. H. Yoo H. S. Lee Y. M. Kie J. H. Jang S. Oh S. (2006). Elevation of sphinganine 1-phosphate as a predictive biomarker for fumonisin exposure and toxicity in mice. J Toxicol Environ Health A 69, 2071–82.
41. Klaassen C. D. (1973). Comparison of the toxicity of chemicals in newborn rats to bile duct-ligated and sham-operated rats and mice. Toxicol Appl Pharmacol 24, 37–44.
42. Koe B. K. Weissman A. (1966). p-Chlorophenylalanine: a specific depletor of brain serotonin. J. Pharmacol Exp Ther 154, 499–516.
43. Kola I. Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3, 711–5.
44. Kramer J. A. (2008). Designing safe drugs: What to consider. Expert Opin Drug Discov 3, 707–13.
45. Kramer J. A. Curtiss S. W. Kolaja K. L. Alden C. L. Blomme E. A. Curtiss W. C. Davila J. C. Jackson C. J. Bunch R. T. (2004). Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profiling. Chem Res Toxicol 17, 463–70.
46. Kramer J. A. Sagartz J. E. Morris D. L. (2007). The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 6, 636–49.
47. Kratz F. Ehling G. Kauffmann H. M. Unger C. (2007). Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Hum Exp Toxicol 26, 19–35.
48. Lindamood C. III Farnell D. R. Giles H. D. Prejean J. D. Collins J. J. Takahashi K. Maronpot R. R. (1992). Subchronic toxicity studies of t-butyl alcohol in rats and mice. Fundam Appl Toxicol 19, 91–100.
49. Luyendyk J. P. Copple B. L. Barton C. C. Ganey P. E. Roth R. A. (2003). Augmentation of aflatoxin B1 hepatotoxicity by endotoxin: involvement of endothelium and the coagulation system. Toxicol Sci 72, 171–81.
50. Mahler J. (1993). NTP technical report on the toxicity studies of tetrachlorophthalic anhydride (CAS No. 117-08-8) administered by gavage to F344/N rats and B6C3F1 mice. Toxic Rep Ser 28, 1–D10.
51. Mahler J. (1997). NTP technical report on toxicity studies of t-butyl alcohol (CAS No. 75-65-0). Administered by inhalation to F344/N rats and B6C3F1 mice. Toxic Rep Ser 53, 1-56, A51–D59.
52. Mannisto P. T. Kirkland D. Viluksela M. Tikkanen L. (1986). Toxicological studies with dithranol and its 10-acyl analogues. Arch Toxicol 59, 180–5.
53. McLaughlin F. Mackintosh J. Hayes B. P. McLaren A. Uings I. J. Salmon P. Humphreys J. Meldrum E. Farrow S. N. (2002). Glucocorticoid-induced osteopenia in the mouse as assessed by histomorphometry, microcomputed tomography, and biochemical markers. Bone 30, 924–30.
54. Miller D. B. Ali S. F. O’Callaghan J. P. Laws S. C. (1998). The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann N Y Acad Sci 844, 153–65.
55. Mitema E. S. Nafstad I. Maribei J. M. (1984). Acute toxicity studies with quinuronium sulfate in laboratory animals and sheep. Toxicol Lett 20, 69–74.
56. National Toxicology Program (NTP) (1987). NTP Toxicology and Carcinogenesis Studies of Bromodichloromethane (CAS No. 75-27-4) in F344/N Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser 321, 1–182.
57. NTP (1992). NTP Toxicology and Carcinogenesis Studies of Methyl Bromide (CAS: 74-83-9) in B6C3F1 Mice (Inhalation Studies). Natl Toxicol Program Tech Rep Ser 385, 1–212.
58. NTP (1993a). NTP Toxicology and Carcinogenesis Studies of Acetaminophen (CAS No. 103-90-2) in F344 Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 394, 1–274.
59. NTP (1993b). NTP Toxicology and Carcinogenesis Studies of Benzyl Acetate (CAS No. 140-11-4) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 431, 1–285.
60. NTP (1993c). Toxicology and Carcinogenesis Studies of 5,5-Diphenylhydantoin (CAS No. 57-41-0) (Phenytoin) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 404, 1–303.
61. NTP (1994). NTP Toxicology and Carcinogenesis Studies of p-Nitrobenzoic Acid (CAS No. 62-23-7) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 442, 1–306.
62. NTP (1996a). NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)-Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser 446, 1–317.
63. NTP (1996b). NTP Toxicology and Carcinogenesis Studies of 2,2-Bis(Bromomethyl)-1,3-Propanediol (FR-1138(R)) (CAS No. 3296-90-0) in F344 Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser. 452, 1–465.
64. NTP (1997a). NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser 457, 1–327.
65. NTP (1997b). NTP Toxicology and Carcinogenesis Studies of t-Butylhydroquinone (CAS No. 1948-33-0) in F344/N Rats and B6C3F(1) Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 459, 1–465.
66. NTP (1998a). NTP Comparative Toxicity Studies of o-, m-, and p-Chloroanilines (CAS Nos. 95-51-2; 108-42-9; and 106-47-8) Administered by Gavage to F344/N Rats and B6C3F1 Mice. Toxic Rep Ser 43, 1–F20.
67. NTP (1998b). NTP Technical Report on the Toxicity Studies of 3,3,’4,4’-Tetrachloroazobenzene (CAS No. 14047-09-7) Administered by Gavage to F344/N Rats and B6C3F1 Mice. Toxic Rep Ser 65, 1–F6.
68. NTP (1998c). NTP Toxicology and Carcinogenesis Studies of Theophylline (CAS No. 58-55-9) in F344/N Rats and B6C3F1 Mice (Feed and Gavage Studies). Natl Toxicol Program Tech Rep Ser 473, 1–326.
69. NTP (1999a). NTP Toxicity Studies of Methyl Ethyl Ketoxime Administered in Drinking Water to F344/N Rats and B6C3F1 Mice (CAS No. 96-29-7). Toxic Rep Ser 51, 1–F9.
70. NTP (1999b). NTP Toxicology and Carcinogenesis Studies of Isobutyraldehyde (CAS No. 78-84-2) in F344/N Rats and B6C3F1 Mice (Inhalation Studies). Natl Toxicol Program Tech Rep Ser 472, 1–242.
71. NTP (2000a). NTP Toxicology and Carcinogenesis Studies of Methyleugenol (CAS NO. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser 491, 1–412.
72. NTP (2000b). NTP Toxicology and Carcinogenesis Studies of Primidone (CAS No. 125-33-7) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 476, 1–290.
73. NTP (2001a). Toxicology and Carcinogenesis Studies of Fumonisin B1 (CAS No. 116355-83-0) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 496, 1–352.
74. NTP (2001b). Toxicology and Carcinogenesis Studies of p,p’-Dichlorophenyl Sulfone (CAS No. 80-07-9) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 501, 7–262.
75. NTP (2004). NTP Technical Report on the Toxicology and Carcinogenesis Studies of Stoddard Solvent IIC (CAS No. 64742-88-7) in F344/N Rats and B6C3F1 Mice (Inhalation Studies). Natl Toxicol Program Tech Rep Ser 519, 1–274.
76. NTP (2006). NTP Toxicology and Carcinogenesis Studies of Bromodichloromethane (CAS No. 75-27-4) in Male F344/N Rats and Female B6C3F1 Mice (Drinking Water Studies). Natl Toxicol Program Tech Rep Ser 532, 1–248.
77. NTP (2007). NTP Toxicology and Carcinogenesis Studies of Diisopropylcarbodiimide (CAS No. 693-13-0) in F344/N Rats and B6C3F1 Mice (Dermal Studies). Natl Toxicol Program Tech Rep Ser 523, 1–286.
78. Nishie K. Waiss A. C. Jr. Keyl A. C. (1969). Toxicity of methylimidazoles. Toxicol Appl Pharmacol 14, 301–7.
79. Olson H. Betton G. Robinson D. Thomas K. Monro A. Kolaja G. Lilly P. Sanders J. Sipes G. Bracken W. Dorato M. Van Deun K. Smith P. Berger B. Heller A. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32, 56–67.
80. Price S. C. Hinton R. H. Mitchell F. E. Hall D. E. Grasso P. Blane G. F. Bridges J. W. (1986). Time and dose study on the response of rats to the hypolipidaemic drug fenofibrate. Toxicology 41, 169–91.
81. Rao M. Rao M. N. (1998). Protective effects of selenomethionine against cisplatin-induced renal toxicity in mice and rats. J Pharm Pharmacol 50, 687–91.
82. Ress N. B. (2002). NTP technical report on the toxicity studies of trans-1,2-dichloroethylene (CAS no. 156-60-5) administered in microcapsules in feed to F344/N rats and B6C3F(1) mice. Toxic Rep Ser, 55, 1–F12.
83. Roberts A. Renwick A. G. Ford G. Creasy D. M. Gaunt I. (1989). The metabolism and testicular toxicity of cyclohexylamine in rats and mice during chronic dietary administration. Toxicol Appl Pharmacol 98, 216–29.
84. Sausen P. J. Teets V. J. Voss K. S. Miller R. T. Cattley R. C. (1995). Gemfibrozil-induced peroxisome proliferation and hepatomegaly in male F344 rats. Cancer Lett 97, 263–8.
85. Smialowicz R. J. Riddle M. M. Williams W. C. Copeland C. B. Luebke R. W. Andrews D. L. (1992). Differences between rats and mice in the immunosuppressive activity of 2-methoxyethanol and 2-methoxyacetic acid. Toxicology 74, 57–67.
86. Steinmetz K. L. Tyson C. K. Meierhenry E. F. Spalding J. W. Mirsalis J. C. (1988). Examination of genotoxicity, toxicity and morphologic alterations in hepatocytes following in vivo or in vitro exposure to methapyrilene. Carcinogenesis 9, 959–63.
87. Suzuki S. Hatashima S. Shinzawa Y. Niwa O. Tamatani R. (1994). Toxicity of neomycin on enzyme activities of kidney and duodenal mucosa in vivo: organ specificity and species difference between rats and mice. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 109, 77–92.
88. Suzuki S. Takamura S. Yoshida J. Shinzawa Y. Niwa O. Tamatani R. (1995). Comparison of gentamicin nephrotoxicity between rats and mice. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 112, 15–28.
89. Tang M. H. Helsby N. A. Goldthorpe M. A. Thompson K. M. Al-Ali S. Tingle M. D. (2007). Hepatic nitroreduction, toxicity and toxicokinetics of the anti-tumour prodrug CB 1954 in mouse and rat. Toxicology 240, 70–85.
90. Thomas C. R. Turner S. L. Jefferson W. H. Bailey C. J. (1998). Prevention of dexamethasone-induced insulin resistance by metformin. Biochem Pharmacol 56, 1145–50.
91. Thompson M. D. Gallagher W. J. Iaizzo P. A. Lanier W. L. (2000). The effect of chronic dexamethasone-induced hyperglycemia and its acute treatment with insulin on brain glucose and glycogen concentrations in rats. Anesthesiology 93, 1279–84.
92. Tingle M. D. Mahmud R. Maggs J. L. Pirmohamed M. Park B. K. (1997). Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. J Pharmacol Exp Ther 283, 817–23.
93. Ueno S. Kashimoto T. Susa N. Ishii M. Chiba T. Mutoh K. Hoshi F. Suzuki T. Sugiyama M. (2003). Comparison of hepatotoxicity and metabolism of butyltin compounds in the liver of mice, rats and guinea pigs. Arch Toxicol 77, 173–81.
94. Ulrich R. Friend S. H. (2002). Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat Rev Drug Discov 1, 84–88.
95. von Keutz E. Schluter G. (1999). Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. J Antimicrob Chemother 43 Suppl B, 91–100.
96. Voss K. A. Liu J. Anderson S. P. Dunn C. Miller J. D. Owen J. R. Riley R. T. Bacon C. W. Corton J. C. (2006). Toxic effects of fumonisin in mouse liver are independent of the peroxisome proliferator-activated receptor alpha. Toxicol Sci 89, 108–19.
97. Waites C. R. Dominick M. A. Sanderson T. P. Schilling B. E. (2007). Nonclinical safety evaluation of muraglitazar, a novel PPAR {alpha}/{gamma} agonist. Toxicol Sci. 100, 248–58.
98. Wilson D. M. Goldsworthy T. L. Popp J. A. Butterworth B. E. (1992). Evaluation of genotoxicity, pathological lesions, and cell proliferation in livers of rats and mice treated with furan. Environ Mol Mutagen 19, 209–22.
99. Woodcock J. Feigal D. Goodman J. Galson S. (2004). Challenge and opportunity on the critical path to new medicinal products. FDA News Press Release.
100. Yang Q. Nagano T. Shah Y. Cheung C. Ito S. Gonzalez F. J. (2008). The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol Sci 101, 132–9.
101. Yapar K. Kart A. Karapehlivan M. Atakisi O. Tunca R. Erginsoy S. Citil M. (2007). Hepatoprotective effect of 1-carnitine against acute acetaminophen toxicity in mice. Exp Toxicol Pathol 59, 121–8.